©
Ludwig Cancer Research Oxford
The Society for Melanoma Research is a diverse organisation of scientific and medical investigators devoted to alleviating the suffering of people with melanoma. The principal goal is to bring together members who vary widely in their professions - from basic researchers to translational researchers to clinicians with a mission to improve the lives of those suffering from melanoma through research.
The Lifetime Achievement Award is presented annually to an individual who has made major and impactful contributions to melanoma research throughout their career.
Professor Colin Goding has worked within Ludwig Oxford since 2008, examining the role of signalling and transcription in melanoma biology with the aim of developing novel and anti-cancer therapies that take tumour phenotypic heterogeneity into account.
In his career to date, Colin has used melanoma as a model in establishing the key role of the Microphthalmia-associated transcription factor (MITF) in microenvironment-driven phenotypic-switching in melanoma biology. MITF-low cells are drug-resistant, slow-cycling, tumour-initiating and invasive, so understanding how MITF is regulated and how it integrates microenvironmental signals to determine melanoma phenotype is a key aim in helping develop effective therapies.
Find out more about the Lifetime Achievement Award on the Society for Melanoma Research website: https://www.societymelanomaresearch.org/awards/lifetime_achievement